Summary for 6ZB2
Entry DOI | 10.2210/pdb6zb2/pdb |
Descriptor | Bromodomain-containing protein 2, 1,2-ETHANEDIOL, ~{N}5-cyclopropyl-1-(1~{H}-indol-4-ylmethyl)-~{N}3-methyl-2-oxidanylidene-pyridine-3,5-dicarboxamide, ... (5 entities in total) |
Functional Keywords | inhibitor, histone, epigenetic reader, bromodomain, brd2, bromodomain containing protein 2, antagonist, transcription |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 14089.18 |
Authors | Chung, C. (deposition date: 2020-06-06, release date: 2020-08-05, Last modification date: 2024-05-01) |
Primary citation | Seal, J.T.,Atkinson, S.J.,Aylott, H.,Bamborough, P.,Chung, C.W.,Copley, R.C.B.,Gordon, L.,Grandi, P.,Gray, J.R.J.,Harrison, L.A.,Hayhow, T.G.,Lindon, M.,Messenger, C.,Michon, A.M.,Mitchell, D.,Preston, A.,Prinjha, R.K.,Rioja, I.,Taylor, S.,Wall, I.D.,Watson, R.J.,Woolven, J.M.,Demont, E.H. The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. J.Med.Chem., 63:9093-9126, 2020 Cited by PubMed: 32702236DOI: 10.1021/acs.jmedchem.0c00796 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.282 Å) |
Structure validation
Download full validation report